| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $48.3M | +10.2% |
| SG&A Expense | $14.7M | +38.7% |
| Operating Income | -$63.0M | -15.7% |
| Income Tax | $0 | — |
| Net Income | -$59.5M | -13.0% |
| EPS (Basic) | -$4.40 | +71.2% |
| EPS (Diluted) | -$4.40 | +71.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $59.0M | -46.7% |
| Current Assets | $60.8M | -46.2% |
| Total Assets | $62.1M | -45.9% |
| Current Liabilities | $5.9M | -43.8% |
| Total Liabilities | $5.9M | -46.4% |
| Stockholders' Equity | $56.2M | -45.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$51.8M | -1.4% |
| Capital Expenditures | $46K | -11.5% |
| Investing Cash Flow | -$46K | -100.3% |
| Financing Cash Flow | $163K | -99.9% |
| Free Cash Flow | -$51.9M | -1.4% |